Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 37 of 116

  1. Bexarotene (targretin)

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule terminated

    1 trial

  2. Bexmarilimab

    Lacuna Pharma Pty Ltd

    Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  3. Bezuclastinib in combination with sunitinib

    Cogent Biosciences

    Gastrointestinal Stromal Tumors

    phase 2 small molecule active

    1 trial

  4. Bicalutamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Neoplasms

    phase 2 small molecule active

    1 trial

  5. BinD19

    The First People's Hospital of Lianyungang

    Relapsed B-cell Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  6. Binimetinib

    United Therapeutics Europe Ltd

    Locally Advanced Pancreatic Carcinoma

    phase 2 small molecule terminated

    1 trial

  7. Binimetinib

    United Therapeutics Europe Ltd

    Metastatic Colorectal Carcinoma

    phase 2 small molecule completed

    1 trial

  8. Bispecific antibody-based combined with CAR-T cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  9. Blinatumomab

    The First People's Hospital of Lianyungang

    B-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  10. Blinatumomab

    Takeda

    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

    phase 2 mab active

    1 trial

  11. Blinatumomab

    BEONE MEDICINES AUS PTY LTD

    B Cell Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  12. Blinatumomab

    Amgen

    B Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  13. Blinatumomab

    BEONE MEDICINES AUS PTY LTD

    Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  14. Blinatumomab SC2

    Amgen

    Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  15. Blinatumomab plus Reduced-dose Chemotherapy

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  16. Blood test

    Yang Xiaotian

    Cancer of Colon

    phase 2 other completed

    1 trial

  17. Bortezomib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Plasma Cell Leukemia

    phase 2 small molecule active

    1 trial

  18. Bortezomib

    Takeda

    Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)

    phase 2 small molecule completed

    1 trial

  19. BreAK CRC 001

    Lacuna Pharma Pty Ltd

    Unresectable locally advanced or metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  20. Brentuximab Vedotin

    Takeda

    Enteropathy Associated T-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  21. Brentuximab Vedotin

    United Therapeutics Europe Ltd

    Ann Arbor Stage IB Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  22. Brentuximab Vedotin in Combination with Tislelizumab

    Takeda

    NK/T Cell Lymphoma Nos

    phase 2 small molecule active

    1 trial

  23. Brentuximab vedotin

    Takeda

    Relapsed or Refractory Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  24. BrentuximabVedotin (BV)

    Takeda

    Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  25. BrigaPED ITCC-098

    AXIM BIOTECHNOLOGIES, INC.

    Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors

    phase 2 small molecule active

    1 trial

  26. Brigatinib

    Takeda

    Lymphoma, Large-Cell, Anaplastic

    phase 2 small molecule completed

    1 trial

  27. Brigatinib

    Takeda

    Anaplastic Large Cell Lymphoma, ALK-Positive

    phase 2 small molecule active

    1 trial

  28. Brigatinib

    Takeda

    Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma

    phase 2 small molecule terminated

    1 trial

  29. Brigatinib

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  30. Budenofalk 4 mg Zäpfchen, placebo to test

    Dr. Falk Pharma GmbH

    Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma

    phase 2 small molecule active

    1 trial

  31. Busulfan

    Children's Hospital of Fudan University

    Juvenile Myelomonocytic Leukemia

    phase 2 small molecule completed

    1 trial

  32. C-145-04

    Iovance Biotherapeutics B.V.

    Recurrent, metastatic, or persistent Cervical Carcinoma

    phase 2 small molecule active

    1 trial

  33. C225 (cetuximab)

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  34. C3651003

    Pfizer Australia Pty Ltd

    Cancer cachexia

    phase 2 small molecule active

    1 trial

  35. C4161001

    Pfizer Australia Pty Ltd

    Breast Cancer, Ovarian Cancer, SCLC (Part 1 also had TNBC and NSCLC)

    phase 2 small molecule active

    1 trial

  36. C4221008

    Pfizer Australia Pty Ltd

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  37. C4221022

    Pfizer Australia Pty Ltd

    MSI-H/dMMR metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  38. C4221023

    Pfizer Australia Pty Ltd

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 2 small molecule active

    1 trial

  39. C4391025

    Pfizer Australia Pty Ltd

    HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  40. C4971006

    Pfizer Australia Pty Ltd

    Relapsed/Refractory Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  41. C6461008

    Pfizer Australia Pty Ltd

    ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    phase 2 small molecule active

    1 trial

  42. C6461013

    Pfizer Australia Pty Ltd

    Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  43. CA001-044

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  44. CA001-050

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  45. CA027-002

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  46. CA043-001

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).

    phase 2 small molecule active

    1 trial

  47. CA0471009

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  48. CA073-1022

    Celgene Europe Limited

    Newly Diagnosed Advanced Stage Follicular Lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.